12 Health Care Stocks Moving In Thursday's Intraday Session
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Express News | Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
Talphera First Half 2024 Earnings: US$0.31 Loss per Share (Vs US$0.40 Loss in 1H 2023)
Maxim Group Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $3
Maxim Group analyst Naz Rahman maintains $Talphera(TLPH.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 28.5% and a total